Chronic Bronchitis
Chronic Bronchitis - Related Videos
01:24
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
0 Views •
2026
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
06:28
An Obstructive Chronic Pancreatitis Model Established Through Electrocoagulation
0 Views •
2025
The present protocol describes a novel approach to modeling chronic obstructive pancreatitis, which involves visualization of the pancreatic duct and electrocoagulation of the pancreatic duct to cause pancreatic duct obstruction.
09:01
Chronic Salmonella Infected Mouse Model
0 Views •
Cited by 12 •
2010
Establish a chronic bacterial infected mouse model with persistent Salmonella typhimurium colonization in intestine for 27 weeks.
09:25
A Craniotomy Surgery Procedure for Chronic Brain Imaging
0 Views •
Cited by 182 •
2008
This video and protocol demonstrate how to implant a glass-covered cranial window in rodents. These preparations can be used for chronic in vivo two-photon imaging of the neocortex over time scales of months. It may also be used for other types of imaging, including optical intrinsic signal imaging.
06:44
Demonstration of Cutaneous Allodynia in Association with Chronic Pelvic Pain
0 Views •
Cited by 22 •
2009
A demonstration of the bedside test for cutaneous allodynia and its clinical implications.
FAQs
Inhaled bronchodilators relax airway smooth muscle, widening narrowed bronchial passages and making airflow easier. This action targets the reversible component of breathing difficulty rather than directly removing the underlying irritant or mucus burden. Pharmacologically, their value lies in symptom reduction and support of lung function, so clinicians can incorporate them into individualized treatment plans for patients with persistent respiratory impairment.
Impaired mucus clearance allows secretions to remain in the bronchi, where they can contribute to continued blockage and persistent symptoms. In chronic bronchitis, irritant-driven inflammation also promotes excess mucus and bronchial-wall thickening. These processes reinforce one another: narrowed, inflamed airways hinder clearance, while retained mucus adds to airflow limitation. This explains why treatment addresses both symptoms and disease burden.
These medicines serve different, selective roles rather than replacing bronchodilation for every patient. Corticosteroids are used to reduce airway inflammation in selected cases, whereas phosphodiesterase-4 inhibitors are also reserved for selected patients. The treatment approach therefore depends on individual circumstances, with the therapeutic aim of reducing symptoms and exacerbations rather than applying identical drug therapy to everyone.
Treatment selection depends on the patient’s symptom pattern, airflow impairment, and risk of exacerbations, together with the inflammatory and mucus-related features of the condition. Inhaled bronchodilators form the main symptom-directed approach, while corticosteroids or phosphodiesterase-4 inhibitors may be considered for selected patients. This individualized strategy links drug choice to expected benefit and overall disease burden.
A practical pharmacologic approach begins by identifying the dominant clinical burden, then selecting inhaled bronchodilation to address airflow-related symptoms. Clinicians can subsequently consider corticosteroids or phosphodiesterase-4 inhibitors when the patient’s circumstances support their use. Treatment is evaluated by its effects on symptoms, lung function, exacerbations, and overall disease burden, allowing therapy to remain individualized.
Pharmacologic treatment is intended to produce several clinically meaningful outcomes: fewer respiratory symptoms, improved lung function, and reduced exacerbations. These endpoints reflect different dimensions of benefit: symptom relief addresses daily breathing difficulty, lung-function improvement reflects airflow, and fewer exacerbations indicates better control over worsening disease. Together, they help assess whether an individualized regimen is reducing overall disease burden.